XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
LICENSING AGREEMENTS AND ACQUISITIONS - Aggregate Acquisition Consideration (Details) - XIIDRA® And Certain Other Ophthalmology Assets Acquisition - Bausch + Lomb
$ in Millions
Sep. 29, 2023
USD ($)
Business Acquisition [Line Items]  
Cash consideration paid to Novartis at closing, per the Acquisition Agreement $ 1,750
Estimated fair value of contingent consideration 3
Preliminary aggregate purchase consideration $ 1,753